In April, the critically acclaimed Tumour Models series will be coming to the Nordics for the first time ever, uniting more than seventy pharma, biotech, and research leaders across the Nordic biotech landscape. 

Attendees joining us in Stockholm this April will explore the most critical topics in tumour modelling for 2025 and beyond through discussions, innovative case studies, and insights from the seventeen expert speakers already confirmed to be presenting. Topics will include leveraging 3D in vitro models for enhanced drug discovery with Roche, advancing humanised mouse models for more accurate preclinical research with Bioinvent, exploring innovative approaches to treating solid tumours with Hemispherian, and optimizing target/receptor axis modelling for precision medicine with Anocca.

Don’t miss this opportunity to collaborate with your peers whilst building new and lasting relationships with forward thinking minds in the Nordic region: https://ter.li/f8zotx 

The Nordic region is rapidly emerging as a global leader in oncology research and with no existing oncology/tumour model centric forum, it became clear this was the next destination for the acclaimed series to call home. Drug developers, and solution providers in this rapidly growing space need to be able to keep up with ever-changing models, advancements, and strategies to de-risk their pipelines and drive forward innovative research. Enter, Tumour Models Summit Nordics, a free-to-attend meeting for drug developers to unite and discuss key evolutions, network, and tackle the challenges that face the industry. 

With the Tumour Models Summit in London celebrating its 13th year, Boston marking its 12th, and San Francisco turning nine, there has never been a better time to launch this eagerly awaited new addition to the Tumour Models family. Tumour Models Summit Nordics follows in the footsteps of its older siblings, bringing unprecedented insight and connection to industry leaders and experts who work to stay at the bleeding-edge of oncology R&D. Will you be one of them?